Parasite vaccines versus anti-parasite drugs: rivals or running mates?
Identifieur interne : 003163 ( Main/Exploration ); précédent : 003162; suivant : 003164Parasite vaccines versus anti-parasite drugs: rivals or running mates?
Auteurs : W. E. Gutteridge [Royaume-Uni]Source :
- Parasitology [ 0031-1820 ] ; 1989-01.
Abstract
Previous articles in this volume have considered the whole question of parasite vaccines from the immunological point of view. A backcloth of general concepts (Roitt, 1989) and strategies in the viral area (Schild, 1989) precedes consideration of problems specific to parasite vaccines (Mitchell, G. F. 1989). This leads on to reviews of progress to date in the development of vaccines for leishmaniasis (Modabber, 1989), malaria (Mitchell, G. H. 1989) and schistosomiasis (Sher, 1989) and in the development and use of veterinary vaccines (Morrison, 1989). I have been asked in this final chapter to take one step back from all of this and provide the alternative, chemotherapeutic, perspective. The reasons for the request are particularly pertinent, though rarely stated: antiparasite drugs already exist; if parasite vaccines are in fact developed, the way these drugs are used and the whole question of whether or not new ones are required, will have to be reconsidered. It is also a timely one: it is clear that the whole concept of a series of vaccines for the control of parasitic diseases has been so well sold, some would say oversold, that it is impacting on the resolve within the pharmaceutical industry to undertake new chemotherapeutic developments, at a time when this is already under severe strain because of financial considerations (Gutteridge, 1987 a). Hence my title: Parasite vaccines versus anti-parasite drugs: rivals or running mates?. I will try to answer it by, in turn, addressing three key questions. Why are we attempting to develop parasite vaccines? Will we be successful? If we are, will there still be a need for chemotherapy?
Url:
DOI: 10.1017/S0031182000072279
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002003
- to stream Istex, to step Curation: 002003
- to stream Istex, to step Checkpoint: 001F28
- to stream Main, to step Merge: 003232
- to stream Main, to step Curation: 003163
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parasite vaccines versus anti-parasite drugs: rivals or running mates?</title><author><name sortKey="Gutteridge, W E" sort="Gutteridge, W E" uniqKey="Gutteridge W" first="W. E." last="Gutteridge">W. E. Gutteridge</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E01A3512F16C4A3BF2DB30C3C2620E4B843702EC</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1017/S0031182000072279</idno><idno type="url">https://api.istex.fr/ark:/67375/6GQ-9JNKTKMD-W/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002003</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002003</idno><idno type="wicri:Area/Istex/Curation">002003</idno><idno type="wicri:Area/Istex/Checkpoint">001F28</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F28</idno><idno type="wicri:doubleKey">0031-1820:1989:Gutteridge W:parasite:vaccines:versus</idno><idno type="wicri:Area/Main/Merge">003232</idno><idno type="wicri:Area/Main/Curation">003163</idno><idno type="wicri:Area/Main/Exploration">003163</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parasite vaccines versus anti-parasite drugs: rivals or running mates?</title><author><name sortKey="Gutteridge, W E" sort="Gutteridge, W E" uniqKey="Gutteridge W" first="W. E." last="Gutteridge">W. E. Gutteridge</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS.</wicri:regionArea><wicri:noRegion>Kent BR3 3BS.</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Parasitology</title><title level="j" type="abbrev">Parasitology</title><idno type="ISSN">0031-1820</idno><idno type="eISSN">1469-8161</idno><imprint><publisher>Cambridge University Press</publisher><pubPlace>Cambridge, UK</pubPlace><date type="published" when="1989-01">1989-01</date><biblScope unit="volume">98</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S87">S87</biblScope><biblScope unit="page" to="S97">S97</biblScope></imprint><idno type="ISSN">0031-1820</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0031-1820</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Previous articles in this volume have considered the whole question of parasite vaccines from the immunological point of view. A backcloth of general concepts (Roitt, 1989) and strategies in the viral area (Schild, 1989) precedes consideration of problems specific to parasite vaccines (Mitchell, G. F. 1989). This leads on to reviews of progress to date in the development of vaccines for leishmaniasis (Modabber, 1989), malaria (Mitchell, G. H. 1989) and schistosomiasis (Sher, 1989) and in the development and use of veterinary vaccines (Morrison, 1989). I have been asked in this final chapter to take one step back from all of this and provide the alternative, chemotherapeutic, perspective. The reasons for the request are particularly pertinent, though rarely stated: antiparasite drugs already exist; if parasite vaccines are in fact developed, the way these drugs are used and the whole question of whether or not new ones are required, will have to be reconsidered. It is also a timely one: it is clear that the whole concept of a series of vaccines for the control of parasitic diseases has been so well sold, some would say oversold, that it is impacting on the resolve within the pharmaceutical industry to undertake new chemotherapeutic developments, at a time when this is already under severe strain because of financial considerations (Gutteridge, 1987 a). Hence my title: Parasite vaccines versus anti-parasite drugs: rivals or running mates?. I will try to answer it by, in turn, addressing three key questions. Why are we attempting to develop parasite vaccines? Will we be successful? If we are, will there still be a need for chemotherapy?</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Gutteridge, W E" sort="Gutteridge, W E" uniqKey="Gutteridge W" first="W. E." last="Gutteridge">W. E. Gutteridge</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003163 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003163 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E01A3512F16C4A3BF2DB30C3C2620E4B843702EC
|texte= Parasite vaccines versus anti-parasite drugs: rivals or running mates?
}}
| This area was generated with Dilib version V0.6.33. |  |